Improving smoking cessation and HIV/TB treatment outcomes in South Africa

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to integrate existing interventions into a new program called QUIT-AD, which focuses on enhancing smoking cessation efforts among individuals living with HIV and/or tuberculosis (TB) in Cape Town, South Africa. The program seeks to address the high prevalence of smoking in this population, which exacerbates health issues related to HIV and TB. By demonstrating feasibility, acceptability, and preliminary efficacy, the intervention could pave the way for larger-scale effectiveness testing. The ultimate goal is to improve public health outcomes by increasing smoking quit rates and facilitating better treatment outcomes for HIV and TB patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Aged 18 or older
2. Willing and able to provide written informed consent
3. Living with HIV, confirmed via medical record, and history of taking ART for at least three months (consecutively or non-consecutively)
4. Within 4 months of initiating or reinitiating TB treatment; positive GeneXpert test or sputum culture
5. Habitual smoker operationalized as smoking at least 4 days a week
6. Motivation (\> 5/10) to quit smoking or \> 24 hour quit past yr
7. Must be living in the catchment area for either the Town Two Clinic or the Michael Mapongwana Community Health Clinic in Khayelitsha

Exclusion Criteria:

1. Current interfering untreated/unstable mental health condition (e.g., psychosis, bipolar dx)
2. Current use of non-study pharmacotherapy for smoking cessation,
3. Cognitive Behavioral Therapy for smoking cessation initiated within the past year,
4. Diagnosed with extra-pulmonary or drug resistant (MDR or XDR) TB based upon chart review

Where it's running

• University of Cape Town
  Rondebosch, South Africa Recruiting

Study contacts

• Principal investigator: Amelia Stanton, PhD — Boston University
• Study coordinator: Conall O'Cleirigh, PhD
• Email: cocleirigh@mgh.harvard.edu
• Phone: 617-643-0385

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Quitting Matters: a smoking quit program for people living with HIV

  This 6-month program will test whether a tailored smartphone app plus nicotine patches and gum helps people living with HIV quit smoking better than a standard quit app.

  Recruiting Wake Forest University Health Sciences · Winston-Salem, North Carolina · NCT06883097

• Doxycycline added to standard treatment for central nervous system tuberculosis

  This trial tests whether adding doxycycline to standard anti‑TB therapy and corticosteroids helps adults with central nervous system tuberculosis live longer or have less severe neurological disability.

  Recruiting at 5 sites Phase 2 National University Hospital, Singapore · Medan, Medan and 5 other locations · NCT06446245

• Smoky Futures: Danish Adolescent Nicotine Use over Time

  This observational cohort follows Danish youths ages 15–25 to see how cigarette, e-cigarette, and other nicotine use begin, change, and affect health and education over several years.

  Recruiting University of Southern Denmark · Copenhagen · NCT07910331

• Biomarker Test for Diagnosis and Monitoring of Extrapulmonary Tuberculosis

  This study tests biomarker-based methods to help diagnose extrapulmonary TB and monitor treatment in adults, including people living with HIV, using samples from affected sites in Kenya.

  Recruiting at 2 sites Nagasaki University · Nairobi and 1 other locations · NCT07901387

• Short-Course TB Treatment for Children with Non-Severe Pulmonary TB

  This trial tests two shorter-treatment options for kids with non-severe pulmonary TB to see if they can clear the infection as well as the standard 6-month plan.

  Recruiting at 13 sites Phase 2 Huashan Hospital · Fuzhou, Fujian and 12 other locations · NCT07893444

• Nicotine Orodispersible Tablet to Relieve Cravings in Smokers

  A nicotine mint orodispersible tablet is tested vs placebo to see if it quickly eases the urge to smoke in adult cigarette smokers.

  Recruiting Phase 2 Kenvue Brands LLC · Mississauga, Ontario · NCT07893158

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.